Long Non-Coding RNA SNHG14 Contributes to the Development of Hepatocellular Carcinoma via Sponging miR-217.
SNHG14
hepatocellular carcinoma
miR-217
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
Thousands of long non-coding RNAs (lncRNAs) have been functionally verified as crucial regulators of physiological processes and disease progressions, yet their roles in hepatocellular carcinoma (HCC) have not been clearly illuminated. We analyzed the expression of lncRNA-SNHG14 in TCGA data via bioinformatic analysis and detected its expression in HCC specimens by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Loss-of-function experiments were used to study the biological function of SNHG14 in HCC cells. RT-qPCR, Western blotting and dual-luciferase reporter assay were carried out to investigate the molecular mechanism of SNHG14 in HCC. The upregulation of lncRNA-SNHG14 was observed in HCC tissues compared with normal tissues via RT-qPCR and bioinformatic analysis of TCGA data. Silencing of SNHG14 inhibited cell proliferation and induced cell apoptosis in HCC cells. microRNA-217 (miR-217), the tumor-suppressive miRNA in HCC, was predicted and confirmed as a miRNA sponged by SNHG14 in HCC cells. Via downregulation of miR-217, SNHG14 increased the expression of several miR-217-related oncogenes and subsequently activated oncogene-related signaling pathways in HCC cells. In addition, inhibition of miR-217 reversed SNHG14 silencing induced decrease of cell proliferation and increase of cell apoptosis. Their association was verified in the published microarray dataset and the collected HCC samples. In summary, SNHG14 is involved in the development of HCC via sponging miR-217 and it may be a biomarker for patients with HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Thousands of long non-coding RNAs (lncRNAs) have been functionally verified as crucial regulators of physiological processes and disease progressions, yet their roles in hepatocellular carcinoma (HCC) have not been clearly illuminated.
METHODS
METHODS
We analyzed the expression of lncRNA-SNHG14 in TCGA data via bioinformatic analysis and detected its expression in HCC specimens by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Loss-of-function experiments were used to study the biological function of SNHG14 in HCC cells. RT-qPCR, Western blotting and dual-luciferase reporter assay were carried out to investigate the molecular mechanism of SNHG14 in HCC.
RESULTS
RESULTS
The upregulation of lncRNA-SNHG14 was observed in HCC tissues compared with normal tissues via RT-qPCR and bioinformatic analysis of TCGA data. Silencing of SNHG14 inhibited cell proliferation and induced cell apoptosis in HCC cells. microRNA-217 (miR-217), the tumor-suppressive miRNA in HCC, was predicted and confirmed as a miRNA sponged by SNHG14 in HCC cells. Via downregulation of miR-217, SNHG14 increased the expression of several miR-217-related oncogenes and subsequently activated oncogene-related signaling pathways in HCC cells. In addition, inhibition of miR-217 reversed SNHG14 silencing induced decrease of cell proliferation and increase of cell apoptosis. Their association was verified in the published microarray dataset and the collected HCC samples.
CONCLUSION
CONCLUSIONS
In summary, SNHG14 is involved in the development of HCC via sponging miR-217 and it may be a biomarker for patients with HCC.
Identifiants
pubmed: 32581548
doi: 10.2147/OTT.S244530
pii: 244530
pmc: PMC7269013
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4865-4876Informations de copyright
© 2020 Xu et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Nature. 2014 Jan 16;505(7483):344-52
pubmed: 24429633
Oncol Rep. 2016 Mar;35(3):1671-9
pubmed: 26708715
Neuroscience. 2017 Apr 21;348:98-106
pubmed: 28215748
Cell Death Dis. 2017 May 11;8(5):e2772
pubmed: 28492542
Mol Cell Biochem. 2014 Jul;392(1-2):289-96
pubmed: 24671492
Eur Rev Med Pharmacol Sci. 2019 May;23(9):3664-3671
pubmed: 31114991
Int J Clin Exp Pathol. 2015 Dec 01;8(12):15677-83
pubmed: 26884837
Sci Rep. 2017 Jul 12;7(1):5186
pubmed: 28701723
Oncol Lett. 2018 May;15(5):7963-7972
pubmed: 29849802
PLoS One. 2017 Apr 24;12(4):e0176395
pubmed: 28437471
Liver Cancer. 2013 Aug;2(3-4):338-44
pubmed: 24400221
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Oncol Rep. 2017 Mar;37(3):1772-1778
pubmed: 28184926
Oncol Lett. 2019 Jun;17(6):5108-5114
pubmed: 31186723
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mol Med Rep. 2017 Nov;16(5):6920-6927
pubmed: 28901526
J Cell Mol Med. 2018 Dec;22(12):5862-5876
pubmed: 30246921
Biomed Pharmacother. 2019 Sep;117:109164
pubmed: 31252267
Cancer Res. 2017 Dec 1;77(23):6704-6716
pubmed: 28947421
Minerva Med. 2017 Apr;108(2):108-113
pubmed: 27879964
World J Gastroenterol. 2015 Nov 28;21(44):12605-11
pubmed: 26640336
J Hepatol. 2017 Sep;67(3):603-618
pubmed: 28438689
Cancer Sci. 2017 Oct;108(10):1927-1933
pubmed: 28776911
Oncogene. 2017 Oct 12;36(41):5661-5667
pubmed: 28604750
Am J Transl Res. 2019 Sep 15;11(9):5897-5904
pubmed: 31632558
J Clin Invest. 2009 Mar;119(3):465-77
pubmed: 19221438
Cell Oncol (Dordr). 2018 Jun;41(3):283-296
pubmed: 29470830
Am J Pathol. 2020 Feb;190(2):469-483
pubmed: 31783009
Cell Oncol (Dordr). 2020 Feb;43(1):137-153
pubmed: 31691159
J Cell Biochem. 2018 Aug;119(8):6905-6913
pubmed: 29667771
J Hepatol. 2016 Jun;64(6):1283-94
pubmed: 26812074
Cell Stem Cell. 2015 Apr 2;16(4):413-25
pubmed: 25842979
J Cell Biochem. 2020 Feb;121(2):1998-2008
pubmed: 31692034